New drug combo targets hard-to-treat BRAF cancers in early trial
Disease control
Completed
This early-phase study tested a new drug called CFT1946, alone or combined with trametinib or cetuximab, in 89 adults with advanced solid tumors that have a BRAF V600 mutation (including melanoma, lung, colon, and thyroid cancers). The main goals were to check safety and find the…
Phase: PHASE1 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated May 01, 2026 15:59 UTC